NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.70 +0.68 (+0.87%) GOLD FUTURES
2,390.00 +30.10 (+1.28%) DOW
39,835.02 +276.91 (+0.70%) Bitcoin GBP
51,662.45 +3,237.18 (+6.68%)
OptiNose, Inc. (OPTN)
| Previous close | 1.1300 |
| Open | 1.1200 |
| Bid | 1.1200 x 1200 |
| Ask | 1.1500 x 900 |
| Day's range | 1.1050 - 1.1400 |
| 52-week range | 0.8000 - 2.1000 |
| Volume | |
| Avg. volume | 1,202,386 |
| Market cap | 132.84M |
| Beta (5Y monthly) | -0.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2024 (GLOB
- GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conf
- GlobeNewswire
Optinose Announces $55 Million Registered Direct Offering
Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024 YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into ag
